Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi Sells 3,502 Shares

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 3,502 shares of Phreesia stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total value of $81,421.50. Following the completion of the transaction, the chief financial officer now directly owns 98,578 shares of the company’s stock, valued at $2,291,938.50. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, July 16th, Balaji Gandhi sold 783 shares of Phreesia stock. The shares were sold at an average price of $23.74, for a total transaction of $18,588.42.

Phreesia Price Performance

Shares of PHR opened at $23.76 on Friday. Phreesia, Inc. has a 52-week low of $12.05 and a 52-week high of $29.16. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.03. The stock has a 50 day moving average price of $23.63 and a 200 day moving average price of $22.75.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. DA Davidson reiterated a “buy” rating and set a $32.00 target price on shares of Phreesia in a report on Thursday, September 5th. Stephens reiterated an “overweight” rating and issued a $28.00 target price on shares of Phreesia in a report on Friday, May 31st. KeyCorp cut their price target on Phreesia from $27.00 to $25.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Truist Financial lifted their price objective on Phreesia from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, September 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $29.00 target price on shares of Phreesia in a research note on Thursday, September 5th. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.42.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. increased its holdings in shares of Phreesia by 5,462.3% in the 4th quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock valued at $89,000 after acquiring an additional 3,769 shares during the period. M&T Bank Corp acquired a new position in Phreesia in the 4th quarter valued at about $527,000. Private Advisor Group LLC purchased a new stake in Phreesia during the 4th quarter valued at approximately $263,000. Charles Schwab Investment Management Inc. lifted its position in Phreesia by 3.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 412,763 shares of the company’s stock worth $9,555,000 after acquiring an additional 15,298 shares during the period. Finally, Brown Advisory Inc. grew its stake in shares of Phreesia by 22.2% in the 4th quarter. Brown Advisory Inc. now owns 3,950,356 shares of the company’s stock valued at $91,451,000 after purchasing an additional 716,374 shares during the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.